Prediction of HD-related clinical outcome progression and imaging markers using AI-based Digital Twins to be Presented at HDTC 2024
We are delighted to announce that Aitia will be at the upcoming 19th Annual Huntington’s Disease Therapeutics Conference being held from February 26-29 in Palm Springs, California. We will be presenting a poster focused on identification of gene pathways with direct causal relationships to Huntington’s Disease (HD) through Gemini Digital Twins of HD patients, based […]
Unveiling the AI Dominance in Biopharma: STAT Post JPM Conference Insights
JPM conference has echoed discussions about AI across the biopharmaceutical landscape. Catch up on key insights shared in the latest STAT article titled: “At Health Care’s Biggest Investor Conference, AI’s High Hopes Collided with Skepticism.” Sanofi’s chief executive, Paul Hudson, revealed the widespread integration of AI within the company: “More than 11,000 people across the […]
Charles River and Aitia Join Forces to Harness AI and Gemini Digital Twins in Advancing Neurodegenerative and Oncology Research
Charles River Laboratories has entered into an agreement granting Aitia access to its artificial intelligence-powered drug solution platform. The objective is to expedite the development of multiple therapy programs targeting neurodegenerative diseases and oncology. Read more on the recent collaboration between Charles River and Aitia, in Fierce Biotech article. Full article available here.
HD Therapeutics Conference Poster | Gemini Digital Twins Identified Both Common and Disease-specific Drivers of Cognitive Progression in Huntington’s and Alzheimer’s Diseases
L.Sun, S.Sathe, X.Shen, P.Ashrap, K.Johnson, S.Sukhram, S.Reddy, S-Y.Shin, J.Latourelle, C.Sampaio
Companies to Focus on Therapeutic Targets Showing Cause and Effect
Aitia has been featured in Huntington’s Disease News for its collaboration with UCB to develop a new treatment for Huntington’s disease. The article highlights Aitia’s expertise in Causal AI as “a new branch of artificial intelligence that goes beyond establishing links between variables: It makes decisions and predictions based on cause and effect.” The collaboration […]
UCB Enters Drug Discovery Collaboration with Aitia
Aitia latest strategic drug discovery collaboration with UCB, focused on the discovery and validation of novel drug targets and drug candidates for Huntington’s disease. The collaboration will combine the use of new drug targets for Huntington’s disease from Aitia’s Gemini Digital Twins with the expertise of UCB in preclinical model systems and drug research in neurodegeneration for advancing […]